HOSPITAL UNIVERSITARIO RUBER
Departamento
University of Ulm
Ulm, AlemaniaPublicaciones en colaboración con investigadores/as de University of Ulm (4)
2022
-
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64
2021
-
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2
2020
-
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)
Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998
2017
-
Advances in the management of HER2-positive early breast cancer
Critical Reviews in Oncology/Hematology, Vol. 119, pp. 113-122